Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management

George Cholankeril, Ronak Patel, Sandeep Khurana, Sanjaya K Satapathy

Abstract
With the prevalence of hepatitis C virus expected to decline, the proportion of hepatocellular carcinoma (HCC) related to non-alcoholic steatohepatitis (NASH) is anticipated to increase exponentially due to the growing epidemic of obesity and diabetes. The annual incidence rate of developing HCC in patients with NASH-related cirrhosis is not clearly understood with rates ranging from 2.6%-12.8%. While multiple new mechanisms have been implicated in the development of HCC in NASH; further prospective long-term studies are needed to validate these findings. Recent evidence has shown a significant proportion of patients with non-alcoholic fatty liver disease and NASH progress to HCC in the absence of cirrhosis. Liver resection and transplantation represent curative therapeutic options in select NASH-related HCC patients but have placed a significant burden to our healthcare resources and utilization. Currently NASH-related HCC is the fastest growing indication for liver transplant in HCC candidates. Increased efforts to implement effective screening and preventative strategies, particularly in non-cirrhotic NASH patients, are needed to reduce the future impact imposed by NASH-related HCC.

Key words: Non-alcoholic steatohepatitis; Cirrhosis; Non-alcoholic fatty liver disease; Obesity; Hepatocellular carcinoma

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Non-alcoholic steatohepatitis (NASH) is antici-
pated to account for a greater proportion of hepatocellular carcinoma (HCC) incidence due to the growing epidemic of obesity and diabetes. Currently NASH-related HCC is the fastest growing indication for liver transplant in HCC candidates. Increased efforts to implement effective screening and preventative strategies particularly in non-cirrhotic NASH patients possibly based on genetic susceptibility are needed to reduce the future impact imposed by NASH-related HCC.

INTRODUCTION

Hepatocellular carcinoma (HCC) accounts for 90% of primary liver cancers worldwide, HCC being the sixth most common cancer, and is the second leading cause of cancer-related death[1]. HCC largely occurs in the background of chronic liver disease and cirrhosis of the liver[2]. The leading liver disease etiologies for cirrhosis in patients with HCC include but are not limited to chronic hepatitis B, chronic hepatitis C virus (HCV), and alcoholic liver disease. With advent of curative treatments for HCV, the risk of progression to cirrhosis and development of HCC secondary to HCV is anticipated to decline. However, in recent years, non-alcoholic fatty liver disease (NAFLD) has quickly risen as one of leading etiologies for liver disease. NAFLD is a spectrum of chronic liver disease ranging from simple hepatic steatosis to liver cell injury and inflammation known as non-alcoholic steatohepatitis (NASH). The rising incidence of NAFLD/NASH has subsequently led to a dramatic rise in NASH-related HCC incidence[3]. Numerous studies have demonstrated that NASH can lead to advanced fibrosis and cirrhosis, thereby increasing the risk of developing HCC[4-6]. Among patients with NAFLD or NASH, liver disease is the third leading cause of death[4], while HCC represents the main cause of death in this group[7]. The cumulative annual incidence rate for developing HCC in patients with NASH-related cirrhosis is approximately 2.4%-12.8%[8]. In the absence of NASH or cirrhosis, NAFLD can present with HCC. These patients usually present with less aggressive tumors and are less likely to be diagnosed by surveillance compared to HCC that develops in the setting of viral hepatitis[9-11]. A similar rising trend has been reported in NASH progressing to HCC in the absence of cirrhosis[12-14]. In NASH, several risk factors for HCC development have been identified including metabolic syndrome and insulin resistance causing changes in serum cytokines, persistent inflammation, and altered gut microflora and bile composition[15].

EPIDEMIOLOGY

Currently, NAFLD affects more than 80 million Americans, making it the most common etiology for liver disease in the United States. With the incidence of obesity, diabetes and metabolic syndrome continuing to increase in the United States and Europe, NAFLD/NASH may become the most common cause of HCC in developed countries in the near future[16]. In 2012, primary liver cancer was recognized overall as the second most common cause of cancer-related death in the world. In the United States, HCC is the most rapidly rising cause of cancer and cancer-related deaths with an incidence that has tripled over the last decade. This high likelihood for mortality reflects a poor prognosis without therapeutic intervention[17]. HCC is the most prevalent histological subtype accounting for 70%-85% of primary liver malignancies[18]. Compared to HCC in alcoholic liver disease and viral hepatitis, there is a lack of strong epidemiological data regarding the incidence and prevalence of HCC in NAFLD[19]. While the prevalence of NAFLD is thought to be highest among Hispanics and Caucasians, the ethnic distribution among NAFLD/NASH-related HCC patients has yet to be defined[20]. NASH-related HCC patients are predominantly male; however, gender has not been proven to be a statistical risk factor NASH progression to HCC[21]. Studies analyzing demographic and clinical characteristics of NASH-related HCC patients are outlined in Table 1. Reports indicate that NASH can be verified by histological evaluation in up to 47% of all NAFLD cases among obese individuals[22,23]. Amongst a growing population of diabetes which has surpassed 26 million in the United States, the prevalence of biopsy-proven NAFLD and NASH has been reported to be as high as 74% and 11%, respectively[24,25].

This rise in the incidence of NASH-related HCC has impacted trends in liver transplantation as well. A retrospective cohort study amongst adult liver transplant recipients from 2002-2012 indicated that there was 4-fold increase in patients undergoing liver transplant for NASH-related HCC compared to 2-fold increase in number of patients undergoing transplantation for HCV-related HCC[26]. During this 10-year span, NASH also became the second leading cause of HCC-related liver transplantation in America, steadily increasing from 8.3% in 2002 to 10.3% in 2007 and to 13.5% in 2012[26], and most likely will surpass 15% by 2017.

PROGRESSION OF NASH/NAFLD TO HCC

NAFLD is the hepatic manifestation of metabolic syndrome, with insulin resistance driving the alteration in physiology. As mentioned earlier, it ranges from isolated hepatic steatosis, to NASH with or without cirrhosis, and progression to HCC. The diagnosis of NASH is based on histological evidence of hepatic steatosis or magnetic resonance spectroscopic evidence > 5% fat accumulation of liver weight without the presence of secondary causes.
such as alcohol abuse, endocrine disorders, chronic HCV infection or familial hypobetalipoproteinemia\textsuperscript{[27]}. Recent evidence has demonstrated an association between NASH and HCC to be exclusive to patients who had progressed to cirrhosis, suggesting causality\textsuperscript{[8]}.

Compared to benign course of simple steatosis, patients with NASH are more likely to develop progressive advanced liver disease. Matteoni et al\textsuperscript{[28]} demonstrated increased rates of cirrhosis in patients with NASH compared to those with fatty liver without NASH (25% vs 3%, respectively), and increased risk of liver disease-related death (11% vs 2%, respectively). In a much larger study across the entire spectrum of NAFLD which included 420 patients, Rafiq et al\textsuperscript{[29]} demonstrated a higher mortality in those with NASH/NAFLD compared to the general population; liver-related deaths occurred in 13% vs < 1% in general population, and 3% of those with NAFLD developed cirrhosis. Another study further confirmed increased rate of liver-related deaths among patients with NASH when compared with those without NASH (17.5% vs 3%, respectively). In patients with compensated cirrhosis, NASH-related cirrhosis patients had better survival outcomes compared to HCV-related cirrhosis patients. However, in decompensated cirrhosis both cohorts had comparable poor outcomes\textsuperscript{[30,31]}. Currently, both the American Association for the Study of Liver Diseases, and the European Association for the Study of Liver Disease recommend screening for HCC in patients with NASH related cirrhosis every 6-12 mo\textsuperscript{[32]}.

### HCC in Non-Cirrhotic NAFLD/NASH

Emerging evidence suggests that a significant proportion of patients with NAFLD-associated HCC, do not have

**Table 1** Reported studies of hepatocellular carcinoma in patients with cirrhotic and non-cirrhotic non-alcoholic fatty liver disease/ non-alcoholic steatohepatitis, and their clinical characteristics

| Ref. | All (n) | NASH/NAFLD (n) | Study type | Clinical characteristics | Cirrhotic NASH with HCC | Non-cirrhotic NASH with HCC |
|------|---------|----------------|------------|-------------------------|-------------------------|-----------------------------|
|      |         |                |            |                         | Histological diagnosis  | Clinical diagnosis          | Histological diagnosis  | Clinical diagnosis          |
| Cotrim et al\textsuperscript{[33]} | 110 110 | Cohort | Age, 67 ± 11 yr; male, 72 (65.5%); non-Hispanic white, N/A | 32 (29.1%) | 58 (52.7%) |
| Van Meer et al\textsuperscript{[34]} | 933 91\textsuperscript{1} | Cohort | Age, 64 yr; male, 60 (66%); non-Hispanic white, N/A | N/A | N/A |
| Shrager et al\textsuperscript{[35]} | 9 9 | Case series | Age, 58 yr; male, 8 (88.9%); non-Hispanic white, N/A | 5 (55.5%) | N/A | 4 (44.4%) |
| Kikuchi et al\textsuperscript{[36]} | 42 38 | Case series | Age, 66.5 yr; male 26 (62%); non-Hispanic white, N/A | 34 | N/A | 4 |
| Chagas et al\textsuperscript{[37]} | 394 7 | Prospective | Age, 63 ± 13 yr; Male 4 (57%); non-Hispanic white, N/A | 6 | N/A | 1 |
| Ertle et al\textsuperscript{[38]} | 150 36 | Cohort | Age, 68.6 ± 8.4 yr; male 32 (88.9%); non-Hispanic white, N/A | 5 | 14\textsuperscript{2} | 10 |
| Tokushige et al\textsuperscript{[39]} | 2299 292 | Cohort | Age, 72 ± 8.4 yr; male, 181 (62%) | 181\textsuperscript{3} | N/A | 111\textsuperscript{3} |
| Hashizume et al\textsuperscript{[40]} | 1310 10 | Case series | Age 71.5 yr; male 6 (66.7%) | 5 | N/A | 4 |
| Kawada et al\textsuperscript{[41]} | 807 8 | Cohort | Age 73 yr; male 3 (60%); | 2 | N/A | 6 |
| Malik et al\textsuperscript{[42]} | 143 143 | Case control | Age 59 ± 7.6 yr; Male 44 (44.9%); non-Hispanic white, N/A | 17 | N/A | 0 |
| Takuma et al\textsuperscript{[43]} | 11 11 | Case series/Literature review | Age 73.8 ± 4.9 yr; male 5 (45%) | 4 | N/A | 7 |
| Perumpail et al\textsuperscript{[44]} | 44 6 | Cohort | Age 72 ± 8 yr; male 5 (83.3%) | NA | NA | 6 |
| Ascha et al\textsuperscript{[45]} | 510 195 | Cohort | Age 56.5 yr; male 86 (44.1%) | NA | NA | N/A |
| Mohamad et al\textsuperscript{[46]} | 83 83 | Cohort retrospective | Age 64.8 ± 10.4 yr; male 54 (65.1%); non-Hispanic White, 77 (92.8%) | 47 | N/A | 36 |

\textsuperscript{1}Histological data available in 86 patients only; \textsuperscript{2}AASLD Radiological criteria used for diagnosis; \textsuperscript{3}Results based on both liver biopsy and abdominal imaging; Differentiating data not available in the study; \textsuperscript{4}Histologic confirmation obtained in 59% of the patients diagnosed with HCC. HCC: Hepatocellular carcinoma; EMT: Epithelial to mesenchymal transition; NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis; N/A: Not available.
histologic evidence of cirrhosis. In a study conducted by Kawada et al., of 1168 patients who underwent hepatic resection for HCC, 6 of 8 patients with NASH-related HCC did not demonstrate cirrhosis. This study suggested that the presence of cirrhosis in NASH-related HCC was lower compared to HCV-related HCC. These data suggest that compared to patients HCV, HCC may develop at an earlier stage than those with NASH. Paradis et al. analyzed 128 HCC patients who were recruited over 12 years, and reported significant number of patients with NASH developed HCC in the absence of fibrosis when compared to HCC in the setting of other underlying chronic liver disease (65% with F0-F2 in NASH group vs 26% in chronic liver disease). To explain this phenomenon in non-cirrhotic NAFLD patients, one proposed hypothesis is the malignant transformation of hepatic adenoma. Few published reports have suggested that in the presence of metabolic syndrome, hepatocellular adenoma may incur a malignant transformation.

**HCC IN CIRRHOTIC NAFLD/NASH**

During the last two decades, various studies have tried to determine the relationship between NAFLD/NASH, cryptogenic cirrhosis and HCC. A recent meta-analyses by White et al. showed that approximately 60% HCC cases attributed to NAFLD/NASH had cirrhosis either before or at the time of diagnosis. This meta analyses also included review of cohort and longitudinal studies which showed that NASH-associated cirrhosis consistently carried an increased HCC risk ranging between 2.4% and 12.8%.

Additionally, this study reported the risk of developing HCC is lower in patients with cirrhosis due to NAFLD/NASH when compared to those with chronic HCV (NAFLD/NASH, 26.9% vs HCV, 19.7%).

The true prevalence of NASH and NASH-related HCC is likely underestimated. In up to 6.9%-29% of HCC, the underlying etiology of liver disease is unknown and is considered secondary to cryptogenic cirrhosis. Features suggestive of NASH are more frequently observed in HCC arising in patients with cryptogenic cirrhosis than in age- and sex-matched HCC patients of well-defined viral or alcoholic etiology. Although the prevalence of NAFLD/NASH-related HCC is not well defined, the increasing incidence of obesity and diabetes, suggests the impact of NAFLD/NASH-related HCC will continue to grow.

**MORTALITY IN NAFLD/NASH**

Long term outcomes in NAFLD and NASH has been evaluated in several studies and distinctive differences between NASH and non-NASH subtypes of NAFLD have been shown. Type 2 diabetes mellitus has been shown to increase the risk of both liver-related mortality and overall mortality in NAFLD patients. In light of these findings NAFLD patients with type II diabetes should be prioritized in future treatment protocols. A population-based study published in 1996 followed 153852 subjects and found that diabetic patients had a standardized incidence ratio of 4.1 for HCC. However, another retrospective analysis from United States Veteran Registry noted increased the risk of primary liver cancer in patients with diabetes only in the presence of other risk factors such as hepatitis C or B or alcoholic cirrhosis. These observations were not supported by further analysis that found an incremented HCC risk in diabetic patients independently from alcoholic liver disease and viral hepatitis. In a recent meta-analyses, Younossi et al. reported that in NAFLD patients, annual incidence of HCC was 0.44 per 1000 person-years (95%CI: 0.29-0.66), whereas for those with NASH, the annual HCC incident rate was 5.29 per 1000 person-years (95%CI: 0.75-37.56). Among NAFLD cohort, the pooled liver-specific and overall mortality incidence rates were 0.77 per 1000 person-years (95%CI: 0.33-1.77 events) and 15.44 per 1000 person-years (95%CI: 11.72-29.34 events), respectively. Among the NASH cohort, the pooled liver-specific and overall mortality incidence rates were 11.77 per 1000 person-years (95%CI: 7.10-19.53 events) and 25.56 per 1000 person-years (95%CI: 6.29-103.8 events), respectively.

Although cardio-vascular (CV) events remain the major cause of death in patients with NAFLD and NASH, the CV mortality rate amongst the NASH and non-NASH subtypes of NAFLD is similar. Since patients with NASH have significantly higher liver-related mortality than those with non-NASH NAFLD, treatment strategies should be designed to ameliorate the risks for cardiovascular mortality. Further, patients with NASH and type 2 diabetes mellitus, will need increased attention and linkage of care to reduce liver disease-related complications and to reduce their risk of HCC.

**RISK FACTORS AND PROPOSED MECHANISMS FOR NASH-RELATED HCC**

Development of HCC in the setting of chronic liver disease is a complex but gradual process that requires transition through a dysplasia-carcinoma sequence. Several putative oncogenic mechanisms has been incriminated that lead to genomic instability, including telomere erosion, chromosome segregation defects and alterations in the DNA-damage-response pathways. Obesity and diabetes are involved in the mechanisms involved in the development of HCC in NAFLD. The development of HCC in NAFLD is likely multifactorial; involving low grade chronic systemic inflammatory response, increased lipid storage and lipotoxicity, gut disbiosis with elevated levels of lipopolysaccharide (LPS) and hyperinsulinemia with insulin resistance and increased IGF levels. In addition patients with HCC from NAFLD in general has a distinctive phenotype with presentation in older age, being less aggressive and less likely to be diagnosed by surveillance compared with HCC caused by viral hepatitis. Other factors such as genetic polymorphism and, increased iron absorption may also lead to development of HCC in NASH. Proposed mechanisms for NASH-related HCC are depicted in Figure 1.
Cytokines carry out the intercellular communication signals, cellular interactions along with growth and differentiation. Disease states cause imbalances in cytokine levels promoting aberrant signaling and modulating inflammatory responses seen in epithelial to mesenchymal transition pathologic process. Imbalances in the levels of cytokines such as tumor necrosis factor (TNF)-alpha, leptin, adiponectin and interleukin-6 (IL-6) play a pivotal role in NASH.

**Obesity**

Obesity is a significant risk for the development of HCC particularly in patients with NASH, who have a higher predisposition for obesity. Obese (body mass index > 30 kg/m²) patients have a reported 1.93-fold higher risk of developing primary liver cancer. Obesity and excessive visceral adipose tissue has been associated with a chronic inflammatory state due to increased levels of leptin. Leptin, a profibrotic and proangiogenic cytokine, activates the Janus kinase (JAK) pathway, thereby initiating an intracellular signaling cascade of pro-inflammatory cytokines. Obesity has also been associated reduced level of adiponectin, an anti-inflammatory cytokine. Additionally, obesity has been associated with other risk factors including insulin resistance, increased hepatic lipid storage and alteration of intestinal microflora.

**Insulin resistance**

Diabetes has shown to be an independent risk factor for the development of HCC in NASH. Excessive fat accumulation and obesity lead to hepatic and peripheral insulin resistance causing compensatory hyperinsulinemia. Evidence supports that insulin and insulin-like growth factor (IGF) may promote the development of primary liver cancer by activating various oncogenic pathways. Both IGF-1 and insulin receptor substrate stimulates growth by activating the mitogen-activate protein kinase (MAPK) pathway and increases the transcription of c-fos and c-jun, known proto-oncogenes. Activation of MAPK pathway subsequently activates the Wnt/β-catenin signaling cascade leading to fibrosis and hepatocarcinogenesis.

**Lipotoxicity**

Increased lipid accumulation in the liver arises from lipolysis within peripheral adipose tissue, dietary sources and de novo hepatic lipogenesis. This increased lipid accumulation causes hepatic lipotoxicity resulting in the excessive production of saturated and monounsaturated free fatty acids (FFAs). These FFAs undergo β-oxidation leading to formation of reactive oxygen species. Reactive oxygen species induce endothelial reticulum stress, mitochondrial damage and gene transcription promoting inflammatory cell signaling pathways.

**Intestinal microflora dysregulation**

Other novel pathogenic pathway between the gut and liver has been demonstrated, which is driven by dietary changes leading to gut dysbiosis that has the potential to generate hepatic inflammation can ultimately influence HCC. In NASH patients, small intestinal bacterial overgrowth and increased TNF-α levels, elevated expression of Toll-like receptor (TLR) 4 and increased levels of serum IL-8 has been demonstrated.

LPS, a major component of outer membrane of gram-negative bacteria, is an endotoxin that causes inflammation upon entering the systemic circulation. The involvement of LPS in the development of HCC is sus-
pected by the observation that LPS removal by gut sterilization results in diminished tumor growth in patients with chronic liver injury. In two recent studies, the investigators observed in NASH patients, increased levels of TNF-alpha, interleukin-8 and elevated expression of TLR 4 and small intestinal bacterial overgrowth. NASH patients also have less gut gram-negative Bacteroides and an increase in alcohol producing bacteria when compared to patients with simple steatosis, which raises a question as to whether these strains are involved in the pathogenesis of NASH.

Several recent studies have identified potential links between gut dysbiosis and NAFLD in both in animal models and humans. There is incremental evidence for gut microbiome in the pathogenesis of NASH based on these findings, suggesting potential therapeutic role of correcting of gut dysbiosis to a more healthy phenotype in limiting progression of NASH. Evidence linking gut microbiota, NASH, and HCC development is reported from Dapito et al. They treated mice with diethylnitrosamine (DEN) followed by carbon tetrachloride (CCL4) to promote fibrosis-driven HCC. They found that TLR4-deficient mice had limited HCC growth; DEN/CCL4-treated wild-type mice that received antibiotics also had reduced tumor growth, suggesting that the microbiota played a role in HCC progression possibly via LPS-TLR4 axis.

Gut microbiota can catalyse generation of secondary bile acids such as deoxycholic acid, which is known to induce DNA damage. Yoshi moto et al. found that DCA can promote the activation of a senescence-associated secretory phenotype in HSCs, reflected by the secretion of IL-1β. Further they observed limited obesity-induced HCC development in the absence of IL-1β, and alleviation of HCC development with antibiotic treatment. In addition, lowering of DCA or feeding of DCA, limited or enhanced HCC growth respectively. Although the role for bile acids in NASH HCC progression need further exploration, these studies certainly lay the foundation for future exploratory studies in both animal models and human.

Genetic polymorphisms

Genetic polymorphism is also one of the factors that may account for development of HCC in NAFLD. Genetic predisposition plays an important role in susceptibility to the metabolic syndrome and NASH. Recent genome-wide association studies have identified single nucleotide polymorphism in the patatin-like phospholipase domain-containing 3 (PNPLA3) gene. Specifically, a C-to-G genotype in the rs738409 gene, encoding the I148M protein variant, determines differences in hepatic fat accumulation. Although the physiological and biological functions of PNPLA3 within the liver, which effect fat accumulation and NASH, remain unclear, the association of rs738409 polymorphisms with HCC is evident.

It has also been suggested a polymorphism in the transmembrane 6 superfamily member 2 gene (TM6SF2) may increase the risk of NASH progression to HCC. TM6SF2 mutation encodes for a loss of function sub-stitution of lysine to glutamic acid. This TM6SF2 variant was associated with liver injury in NAFLD and NASH patients. While there is an increased prevalence of the TM6SF2 variant in NAFLD and NASH patients, conflicting preliminary data exists regarding its role in the progression to HCC.

Other risk factors

Increased intrahepatic iron accumulation has been associated with NASH progression to HCC. Although clinical data is limited, Sorrentino et al. demonstrated higher hepatic iron storage levels among NASH-related HCC patients compared to NASH patients. The underlying mechanism of increased iron absorption in NASH patients may be related to oxidative DNA damage but further studies are required to understand the role of iron accumulation in NAFLD and HCC.

Other significant risk factors for NASH progression to HCC include advanced age and concomitant chronic alcohol consumption. Alcohol consumption among NASH patients has an associated 3.6-fold increased risk for development of HCC. Also emerging evidence has suggested a possible correlation between obstructive sleep apnea and NAFLD and NASH but its association to development of HCC has not been investigated.

SURVEILLANCE

With the increasing prevalence of NAFLD/NASH and associated HCC, chemopreventive and perhaps reconsideration of current surveillance guidelines are needed. The current AASLD guidelines recommend screening for HCC every 6 mo in patients with cirrhosis. However, the current guidelines lack recommendations for surveillance of NASH patients without cirrhosis who are at risk for developing HCC. This is further supported by a study performed by Mittal et al. in which the data collected on about 1500 HCC patients where HCC related to NASH received less surveillance and treatment compared with patients with cirrhosis and treatment compared with HCC arising in underlying etiologies related to HCV and alcohol.

The lack of longitudinal data in the non-cirrhotic NASH population makes it difficult to develop good evidence-based screening guideline. There is a need for studies addressing the screening guidelines for surveillance of HCC in NASH particularly for non-cirrhotic individuals. We suspect that earlier screening may be needed in patients with NASH who have multiple risk factors for HCC.

CURRENT THERAPEUTIC OPTIONS

The biological heterogeneity of HCC makes it difficult to clarify the key mechanisms of cancer development and thus to develop and implement effective therapies. A few chemopreventive agents have shown promise in the prevention and treatment of steatohepatitis and fibrosis; however these are small individual studies and thus there is a lack of a general consensus due to paucity of evidence.
of data. There is currently no effective chemoprevention to decrease the incidence of HCC. Exceptions include nucleoside analogues used to reduce viral replication in those with hepatitis B, and DAAs for HCV which have very high cure rates.\(^\text{[81]}\).

**Medical therapy**

Regular exercise and controlled caloric intake is the mainstay of therapy for NAFLD, however the extent to which these are effective to prevent the development of HCC is unclear. Physical activity has been reported to have a preventive effect on development of HCC. A large prospective cohort study, which included over 400000 participants suggested that increased physical activity might have a role in HCC prevention that is independent of weight reduction.\(^\text{[82]}\). Preliminary data suggests that statins, metformin and S-Adenosylmethionine are potential chemopreventive agents.\(^\text{[16]}\)

Patients with NASH have been found to be deficient in vitamin E and D; vitamin D deficiency is thought to play a role in hepatic carcinogenesis.\(^\text{[83,84]}\) Other dietary antioxidants such as vitamin C, selenium, coenzyme Q12 and certain phytochemicals have also been touted have chemopreventive potential.\(^\text{[85]}\). NASH patients have been shown to have low levels of serum lycopene.\(^\text{[83]}\) There is a strong inverse relationship between serum lycopene levels and the risk of GI cancers.\(^\text{[86]}\)

Metformin has an antitumor effect in HCC via suppression of mTOR pathway.\(^\text{[87]}\). Although it may not have a role in the treatment of NASH, metformin may have a role in decreasing the incidence of HCC in NASH.\(^\text{[16]}\) A review of two recent meta-analyses included 22650 cases of HCC in approximately 334000 patients with type 2 diabetes revealed that metformin reduced incidence of HCC by 50% whereas sulfonlurea and insulin increased incidence of HCC by 62% and 161% respectively.\(^\text{[88]}\) The use of metformin has also been shown to increase survival of HCC patients who have cirrhosis.\(^\text{[89]}\)

Statins have shown a protective effect in individuals who are at risk for development of steatohepatitis and F2-F4 fibrosis.\(^\text{[90]}\) The protective effect of statins in diabetics is thought to be due to anti-inflammatory properties of statins mediated through the inhibition of JAK.\(^\text{[91]}\) A recent Swedish case control study which evaluated almost 4000 HCC patients treated with statin that were matched with 19970 controls showed that the odds ratio for HCC amongst statin users was 0.88, suggesting a modest but beneficial effect of statins in reducing the risk of HCC.\(^\text{[92]}\)

The heterogeneity of HCC makes it difficult to clarify the mechanism of cancer development and to develop effective therapeutics. However, an integrative functional genomics approach will contribute to the discovery of potential molecular features critical for HCC development. These studies will provide us with better treatment strategies that may be effective to treat all HCC patients including those with NASH.

**Surgical therapy**

Curative treatment options including liver resection and liver transplantation in select early-stage HCC candidates. The Barcelona Clinic Liver Cancer staging system and therapeutic algorithm has been applied to HCC candidates including those with NASH-related HCC.\(^\text{[93]}\) Non-cirrhotic NASH-related HCC patients who underwent curative surgical resection have shown to have superior survival than those with HCV and alcohol-related HCC.\(^\text{[11]}\)

Since the implementation of the Model for End-Stage Liver Disease (MELD) system for liver allocation in 2002 the number of HCC liver transplantsations has dramatically increased. In 2012, they accounted for 23.2% of all liver transplantsations in the United States.\(^\text{[26]}\) HCC liver candidates are eligible to receive a MELD exception which upgrades their priority and thus, increases their likelihood of receiving liver transplant and survival. Subsequently, a higher number of HCC candidates have sought listing for liver transplant. A recent study using United Network for Organ Sharing data from 2004-2013 demonstrated that NASH-related HCC candidates have lower rates for receiving MELD exception and have longer time to transplant compared to HCV-related HCC. Despite this, NASH-related HCC was the fastest growing indication for liver transplantation from 2002-2012.\(^\text{[28]}\) NASH-related HCC liver transplant recipients have better outcomes compared HCV-related HCC with a 5-year post-transplant survival approaching 68%.\(^\text{[85]}\) NASH-related HCC liver transplant recipients with morbid obesity and CV risk factors tend to have poorer outcomes.\(^\text{[96]}\) Further research is needed to evaluate NASH-related HCC post liver transplant survival risk factors and exploring why this growing cohort is less likely to receive a MELD exception.

**CONCLUSION**

With the prevalence of HCV expected to decline, NASH is anticipated to account for a greater proportion of HCC incidence in the near future due to the growing epidemic of obesity and diabetes. The annual incidence rate of developing HCC in patients with NASH-related cirrhosis is not clearly understood with rates ranging from 2.6%-12.8%. Recent evidence has shown a significant proportion of patients with NAFLD and NASH progress to HCC in the absence of cirrhosis. While liver resection and transplantation represent curative therapeutic options in select NASH-related HCC candidates, they also have placed a significant burden to our healthcare resources and utilization. Currently NASH-related HCC is the fastest growing indication for liver transplant in HCC candidates. Increased efforts to implement effective screening and preventative strategies, particularly in non-cirrhotic NASH cohort, are needed to reduce the future impact imposed by NASH and NASH-related HCC.

**REFERENCES**

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008. GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917 [PMID: 21351269 DOI: 10.1002/ijc.25516]
April 18, 2017 | Volume 9 | Issue 11 | 541

Cholankeril G et al. HCC in non-alcoholic steatohepatitis

Younossi ZM, Venkatases C. A 2012 clinical update for internists in adult nonalcoholic fatty liver disease. Panminerva Med 2012; 54: 29-37 [PMID: 22278114]

Venkatases C, Younossi ZM. Potential mechanisms underlying the associations between liver enzymes and risk for type 2 diabetes. Hepatology 2012; 55: 968-970 [PMID: 22362600 DOI: 10.1002/hep.24769]

Thorgerisson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002; 31: 339-346 [PMID: 12149612 DOI: 10.1038/ng0802-339]

Faraal PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from gene to environment. Nat Rev Cancer 2006; 6: 674-687 [PMID: 16929233 DOI: 10.1038/nrc1934]

Schett G, Elewaut D, Mclnnes IB, Dayer JM, Neurath MF. How cytokine networks fuel inflammation: Toward a cytokine-based disease taxonomy. Nat Med 2013; 19: 822-824 [PMID: 23836224 DOI: 10.1038/nm.3260]

Maddur MS, Miossec P, Kaveri SV, Bayry J. Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol 2012; 181: 8-18 [PMID: 22640807 DOI: 10.1016/j.ajpath.2012.03.044]

Grivennikov SI, Karin M. Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis 2011; 70 Suppl 1: i104-i108 [PMID: 21339221 DOI: 10.1136/ard.2010.140145]

Chetrouh O, Lequoy M, Fartoux L, Vigouroux C, Desbois-Mouthon C. Hyperinsulinemia and insulin signalling in the pathogenesis and the clinical course of hepatocellular carcinoma. Liver Int 2015; 35: 2203-2217 [PMID: 26123841 DOI: 10.1111/liv.12903]

Siddique A, Kowdley KV. Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma. Clin Liver Dis 2011; 15: 281-296, vii-x [PMID: 21689613 DOI: 10.1016/j.clindis.2013.03.007]

Ueyama M, Nishida N, Korenaga M, Korenaga K, Kumagai E, Yamaori H, Adachi H, Katsuyama H, Moriyama S, Hamasaki H, Sako A, Sugiyama M, Aoki Y, Inamura M, Murata K, Masaki N, Kagawauchi T, Torimura T, Hyogo H, Aikata H, Ito K, Sumida Y, Kanazawa A, Wataba K, Okamoto K, Honda K, Kon K, Kanto T, Mizokami M, Watanabe S. The impact of PNPLA3 and JAZF1 on hepatocellular carcinoma in non-viral hepatitis patients with type 2 diabetes mellitus. J Gastroenterol 2016; 51: 370-379 [PMID: 23633715 DOI: 10.1007/s00535-015-1116-6]

Buzzetti E, Pinzani M, Tsatschlis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 2016; 65: 1038-1048 [PMID: 26823198 DOI: 10.1016/j.metabol.2015.12.012]

Hirsova P, Ibrham SH, Gores GJ, Malhi H. Lipotoxic lethal and sublethal stress signalling in hepatocytes: relevance to NASH pathogenesis. J Lipid Res 2016; 57: 1758-1770 [PMID: 27040024 DOI: 10.1194/jlr.R066357]

Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001; 48: 206-211 [PMID: 11516641]

Shanahan F, Scully P, Crosbie O, Buckley M, O'Mahony L, Shanahan F, Gazzarone S, Murphy E, Quigley EM. Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with toll-like receptor 4 expression and plasma levels of interleukin 8. Dig Dis Sci 2011; 56: 1524-1534 [PMID: 21064243 DOI: 10.1007/s10620-010-1447-3]

Yoshimoto S, Loo TM, Aratashi K, Kanda H, Sato S, Oyadomari S, Iwakura Y, Oshima K, Morita H, Hattori M, Honda K, Ishikawa Y, Hara E, Ohtani N. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013; 499: 97-101 [PMID: 23803760 DOI: 10.1038/nature12347]

Dapito DH, Mencin A, Gwak GY, Pradere JP, Jang MK, Mederacke I, Caviglia JM, Khiabian H, Aydede Y, Bataller R.
Cholankeril G et al. HCC in non-alcoholic steatohepatitis
van Meer S, van Erpecum KJ, Sprengers D, Klümpen HJ, Jansen PL, Ijzermans JN, Siersema PD, de Man RA, Verheij J. Hepatocellular carcinoma in noncirrhotic livers is associated with steatosis rather than steatohepatitis: potential implications for pathogenesis. *Eur J Gastroenterol Hepatol* 2016; 28: 955-962 [PMID: 27196679 DOI: 10.1097/meg.0000000000000641]

Shrager B, Jibara GA, Tabrizian P, Roayaie S, Ward SC. Resection of nonalcoholic steatohepatitis-associated hepatocellular carcinoma: a Western experience. *Int J Surg Oncol* 2012; 2012: 915128 [PMID: 22988496 DOI: 10.1155/2012/915128]

Chagas AL, Kikuchi LO, Oliveira CP, Vezozzo DC, Mello ES, Oliveira AC, Cella LC, Herman P, Bachella T, Caldwell SH, Alves VA, Carrilho FJ. Does hepatocellular carcinoma in non-alcoholic steatohepatitis exist in cirrhotic and non-cirrhotic patients? *Braz J Med Biol Res* 2009; 42: 958-962 [PMID: 19787150]

Ertle J, Dechêne A, Sowa JP, Penndorf V, Herzer K, Kaiser G, Schlaak JF, Gerken G, Syn WK, Canbay A. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. *Int J Cancer* 2011; 128: 2436-2443 [PMID: 21128245 DOI: 10.1002/ijc.25797]

Hashizume H, Sato K, Takagi H, Hirokawa T, Kojima A, Sohara N, Kakizaki S, Mochida Y, Shimura T, Sunose Y, Ohwada S, Mori M. Primary liver cancers with nonalcoholic steatohepatitis. *Eur J Gastroenterol Hepatol* 2007; 19: 827-834 [PMID: 17873605 DOI: 10.1097/MEG.0b013e328274afcf]

Malik SM, Gugpe PA, de Vera ME, Ahmad J. Liver transplantation in patients with nonalcoholic steatohepatitis-related hepatocellular carcinoma. *Clin Gastroenterol Hepatol* 2009; 7: 800-806 [PMID: 19281869 DOI: 10.1016/j.cgh.2009.02.025]

Takuma Y, Nouso K. Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review. *World J Gastroenterol* 2010; 16: 1436-1441 [PMID: 20333782]

Perumpail RB, Wong RJ, Ahmed A, Harrison SA. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience. *Dig Dis Sci* 2015; 60: 3142-3148 [PMID: 26250831 DOI: 10.1007/s10620-015-3821-7]

Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. *Liverology* 2010; 51: 1972-1978 [PMID: 20209604 DOI: 10.1002/hep.23527]

Mohamad B, Shah V, Onyshchenko M, Elshamy M, Aucejo F, Lopez R, Hanouneh IA, Alhaddad R, Alkhouri N. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis. *Hepatol Int* 2016; 10: 632-639 [PMID: 26558795 DOI: 10.1007/s12072-015-9679-0]
